A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

The effects they have on your body and mind vary, as Wegovy flips one appetite switch in your brain, while Mounjaro flips two ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

Steve Christo – Corbis/Getty Images Semaglutide is a GLP-1 agonist medication that can assist with diabetes management and weight loss ... Participants received 2.4mg injections of semaglutide ...